BIXT — Bioxytran Income Statement
0.000.00%
Last trade - 00:00- $6.62m
- $7.50m
Annual income statement for Bioxytran, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Total Operating Expenses | 1.27 | 4.21 | 2.14 | 3.81 | 2.23 |
| Operating Profit | -1.27 | -4.21 | -2.14 | -3.81 | -2.23 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -2.54 | -4.53 | -2.66 | -4.56 | -2.38 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -2.54 | -4.53 | -2.66 | -4.56 | -2.38 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -2.48 | -4.03 | -2.46 | -4.47 | -2.37 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -2.48 | -4.03 | -2.46 | -4.47 | -2.37 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.026 | -0.038 | -0.021 | -0.033 | -0.017 |